

## NOTES ON NEW PREPARATIONS

### “ ROVAMYCIN ”

May & Baker (India) Private Ltd. announce the introduction in India of the oral antibiotic, “ Rovamycin ” brand spiramycin.

This is a narrow-spectrum antibiotic isolated from *streptomyces ambofaciens* in France in 1951: Spiramycin is markedly active against Gram-positive cocci, and only weakly so against Gram-negative bacteria. It has been found to be remarkably well-tolerated by adults and children alike.

“ Rovamycin ” can be used to treat infections due to *staphylococci*, particularly those strains refractory to penicillin and notably in staphylococcal enteritis associated with the use of broad-spectrum antibiotics. It is also indicated for pneumococcal and streptococcal infections, particularly those of the lung, respiratory tract and middle ear and for the treatment of non-specific urethritis.

“ Rovamycin ” is especially indicated for the treatment of those patients who cannot tolerate other antibiotics and those whose infections are due to organisms which are resistant to such substances.

“ Revamycin ” is supplied in containers of 20x250 mg. capsules.

### THE NEW FORM OF TETRACYCLINE FOR INTRAVENOUS ADMINISTRATION

Squibb N-(pyrrolidinomethyl) tetracycline, a new highly soluble derivative of Tetrachline, is now available as VELACYCLINE INTRAVENOUS.

VELACYCLINE INTRAVENOUS with its high solubility over the entire physiological pH range is well adapted for intravenous therapy. VELACYCLINE INTRAVENOUS can therefore, be administered directly into the vein within two minutes.

For more detailed information on VELACYCLINE INTRAVENOUS. Please write to Sarabhai Chemicals, 13 Wittet Road, Bombay-1.

---

